Prof. Esteban Cvitkovic is a medical oncologist focused on early stage development of single agent and combination regimens and is an advisor to the Medicxi investment team. He has been active in his field for over 40 years, the first 25 years as an academic investigator, and then through a CRO specialized in oncology. The author of over 230 scientific articles and 800 abstracts, Esteban has been responsible for defining the clinical utility and enabling the registration of a variety of oncology drugs. Highlights of his career in industry include co-founding the Index Ventures company OncoEthix (sold to Merck Pharmaceuticals), devoted to novel therapeutic leads and focused on the early development of the first bromodomain inhibitor.
Esteban heads the Scientific Board of the Foundation Nélia & Amadeo Barletta, a non-profit entity that supports translational research for individual cancer treatment, and serves on scientific boards for several biotechnology companies.
Esteban did his clinical and oncology training in Buenos Aires, Institute Tumori, Milan and Memorial Sloan Kettering, New York, and his pharmacology training at Mario Negri in Milan.